Ubiquitin signaling in pancreatic ductal adenocarcinoma

被引:2
|
作者
Lv, Shengnan [1 ]
Zhang, Jian [1 ]
Peng, Xinyu [1 ]
Liu, Huan [1 ]
Liu, Yan [2 ]
Wei, Feng [1 ]
机构
[1] First Hosp Jilin Univ, Gen Surg Ctr, Dept Hepatobiliary & Pancreat Surg, Changchun, Jilin, Peoples R China
[2] Chinese Acad Agr Sci, Changchun Vet Res Inst, Key Lab Jilin Prov Zoonosis Prevent & Control, Changchun, Peoples R China
基金
中国国家自然科学基金;
关键词
pancreatic ductal adenocarcinoma; ubiquitination; ubiquitin-protein ligases; deubiquitinating enzymes; proteolysis-targeting chimeras; CANCER PROGRESSION; ACHIEVES SAFE; BETA-CATENIN; PROMOTES; GROWTH; PROTAC; CHEMORESISTANCE; EXPRESSION; PROTEINS; PROLIFERATION;
D O I
10.3389/fmolb.2023.1304639
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignant tumor of the digestive system, characterized by rapid progression and being prone to metastasis. Few effective treatment options are available for PDAC, and its 5-year survival rate is less than 9%. Many cell biological and signaling events are involved in the development of PDAC, among which protein post-translational modifications (PTMs), such as ubiquitination, play crucial roles. Catalyzed mostly by a three-enzyme cascade, ubiquitination induces changes in protein activity mainly by altering their stability in PDAC. Due to their role in substrate recognition, E3 ubiquitin ligases (E3s) dictate the outcome of the modification. Ubiquitination can be reversed by deubiquitylases (DUBs), which, in return, modified proteins to their native form. Dysregulation of E3s or DUBs that disrupt protein homeostasis is involved in PDAC. Moreover, the ubiquitination system has been exploited to develop therapeutic strategies, such as proteolysis-targeting chimeras (PROTACs). In this review, we summarize recent progress in our understanding of the role of ubiquitination in the development of PDAC and offer perspectives in the design of new therapies against this highly challenging disease.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Genomics of pancreatic ductal adenocarcinoma
    Christian Pilarsky
    Robert Grützmann
    Hepatobiliary & Pancreatic Diseases International, 2014, 13 (04) : 381 - 385
  • [42] Familial Pancreatic Ductal Adenocarcinoma
    Diaz, Kelly E.
    Lucas, Aimee L.
    AMERICAN JOURNAL OF PATHOLOGY, 2019, 189 (01): : 36 - 43
  • [43] MicroRNAs in pancreatic ductal adenocarcinoma
    Jong Y Park
    James Helm
    Domenico Coppola
    Donghwa Kim
    Mokenge Malafa
    Seung Joon Kim
    World Journal of Gastroenterology, 2011, 17 (07) : 817 - 827
  • [44] Pancreatic ductal adenocarcinoma staging
    Al-Hawary, Mahmoud M.
    Francis, Isaac R.
    CANCER IMAGING, 2013, 13 (03): : 360 - 364
  • [45] Mimics of pancreatic ductal adenocarcinoma
    Al-Hawary, Mahmoud M.
    Kaza, Ravi K.
    Azar, Shadi F.
    Ruma, Julie A.
    Francis, Isaac R.
    CANCER IMAGING, 2013, 13 (03) : 342 - 349
  • [46] Aquaporins in pancreatic ductal adenocarcinoma
    Bruun-Sorensen, Anne Sofie
    Edamana, Sarannya
    Login, Frederic H.
    Borgquist, Signe
    Nejsum, Lene N.
    APMIS, 2021, 129 (12) : 700 - 705
  • [47] Biomarkers in pancreatic ductal adenocarcinoma
    J. Gallego
    C. López
    R. Pazo-Cid
    F. López-Ríos
    A. Carrato
    Clinical and Translational Oncology, 2017, 19 : 1430 - 1437
  • [48] Microbiome and pancreatic ductal adenocarcinoma
    Tijeras-Raballand, Annemilai
    Hilmi, Marc
    Astorgues-Xerri, Lucile
    Nicolle, Remy
    Bieche, Ivan
    Neuzillet, Cindy
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2021, 45 (02)
  • [49] Syndecans and Pancreatic Ductal Adenocarcinoma
    Betriu, Nausika
    Bertran-Mas, Juan
    Andreeva, Anna
    Semino, Carlos E.
    BIOMOLECULES, 2021, 11 (03) : 1 - 23
  • [50] Surgery for pancreatic ductal adenocarcinoma
    R. Vera
    L. Díez
    E. Martín Pérez
    J. C. Plaza
    A. Sanjuanbenito
    A. Carrato
    Clinical and Translational Oncology, 2017, 19 : 1303 - 1311